A decision-analytic model of idelalisib and rituximab combination therapy versus rituximab monotherapy in relapsed, unfit chronic lymphocytic leukemia.
Alexander Xenakis
Consultant or Advisory Role - Gilead Sciences
Nathaniel Smith
Consultant or Advisory Role - Gilead Sciences
Rachel Beckerman
Consultant or Advisory Role - Gilead Sciences
Jagpreet Chhatwal
Consultant or Advisory Role - Gilead Sciences
Stephanie A. Gregory
Consultant or Advisory Role - Gilead Sciences
Javier Pinilla-Ibarz
Consultant or Advisory Role - Gilead Sciences
Andrew Briggs
Consultant or Advisory Role - Gilead Sciences